Research programme: fibroblast autologous cell therapies - Fibrocell/Intrexon

Drug Profile

Research programme: fibroblast autologous cell therapies - Fibrocell/Intrexon

Alternative Names: FCX 013; Genetically-modified autologous fibroblasts - Fibrocell Science/Intrexon; genetically-modified human dermal fibroblast, collagen VII

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator Fibrocell Science
  • Developer Fibrocell Science; Intrexon Corporation
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cell replacements; Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Circumscribed scleroderma; Epidermolysis bullosa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Circumscribed scleroderma; Ehlers-Danlos syndrome; Eosinophilia; Psoriasis
  • Research Arthritis

Most Recent Events

  • 25 Apr 2016 FCX 013 receives Orphan Drug status for Circumscribed scleroderma in USA
  • 27 Jan 2016 Interim pharmacodynamics data from a preclinical study in Scleroderma released by Fibrocell
  • 04 Jan 2016 Fibrocell and Intrexon expand collaboration for genetically-modified fibroblasts to include Joint disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top